Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Technological advances in adoptive immunotherapy.

Mathias Oelke1, Christine Krueger, Jonathan P Schneck

  • 1Department of Pathology & Medicine, The Johns Hopkins School of Medicine, Baltimore, Maryland 21205-2196, USA. bmpe5@cs.com

Drugs of Today (Barcelona, Spain : 1998)
|March 9, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Oversimplified immunology is holding biomaterials back.

Nature reviews bioengineering·2026
Same author

Lipid nanoparticle composition directs systemic trafficking and tissue-specific T cell immunity after intramuscular injection.

Nature biomedical engineering·2026
Same author

Engineering age-adaptive mRNA lipid nanoparticle cancer vaccines via reprogramming systemic gene expression.

bioRxiv : the preprint server for biology·2026
Same author

PIK3CA mutant cervical cancer is selectively suppressed by PI3Kα inhibition (Alpelisib/BYL-719 and Inavolisib/GDC-0077) and cooperates with HPV directed T cell therapy.

Neoplasia (New York, N.Y.)·2026
Same author

Biodegradable targeted polymeric mRNA nanoparticles enable in vivo CD19 CAR T cell generation and lead to B cell depletion.

Science advances·2026
Same author

A Three-subtype Molecular model of Cervical Cancer: Multiple PI3K Pathway inhibitors suppress growth and cooperate with HPV-directed immunotherapy.

medRxiv : the preprint server for health sciences·2026
Same journal

Monoclonal antibodies for treatment of osteoporosis.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Tebentafusp: a novel drug for the treatment of metastatic uveal melanoma.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Sugemalimab, a novel PD-L1 inhibitor for treatment of advanced or metastatic non-small cell lung cancer.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Secukinumab, ixekizumab, bimekizumab and brodalumab for psoriasis and psoriatic arthritis.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Mitapivat for sickle cell disease and thalassemia.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Cenegermin for the treatment of dry eye disease.

Drugs of today (Barcelona, Spain : 1998)·2023
See all related articles

New artificial approaches enhance adoptive immunotherapy by overcoming limitations of current dendritic cell and T-cell expansion methods. This aims to improve feasibility and effectiveness for treating diseases like cancer and infections.

Area of Science:

  • Immunology
  • Biotechnology
  • Cell Therapy

Background:

  • Adoptive immunotherapy offers a promising strategy for life-threatening diseases.
  • Current methods for generating antigen-specific T cells (CD4+ and CD8+) face challenges in reproducibility and economic viability.
  • Existing approaches often rely on autologous peptide-pulsed dendritic cells or non-specific T-cell expansion.

Purpose of the Study:

  • To review technological advancements improving adoptive immunotherapy.
  • To address limitations of current dendritic cell-based and T-cell expansion strategies.
  • To enhance the feasibility and effectiveness of adoptive T-cell therapy.

Main Methods:

  • Focus on artificial antigen-presenting cells (aAPCs).
  • Exploration of T-cell receptor (TCR) gene transfer techniques.

Related Experiment Videos

  • Review of strategies for generating antigen-specific T cells.

    • Main Results:

    • Artificial approaches aim to overcome limitations of dendritic cells and non-specific T-cell expansion.
    • New technologies are being developed to make adoptive immunotherapy more reproducible and cost-effective.
    • Advancements facilitate the generation of antigen-specific T cells for therapeutic applications.

    Conclusions:

    • Technological innovations are crucial for advancing adoptive immunotherapy.
    • Artificial antigen-presenting cells and TCR gene transfer represent key strategies.
    • Improved methods will increase the availability and efficacy of adoptive immunotherapy for various diseases.